Pamir Ozan 4

What Happened Pamir Ozan, Chief Financial Officer of Niagen Bioscience (NAGE), acquired 4,255 shares on June 30, 2026. The shares were acquired at $2.71 each for a total value of $11,531. The transaction is an acquisition (award/purchase) under the issuer's employee stock purchase plan rather than a sale.

Key Details

• Transaction date and price: 2026-06-30 at $2.71 per share.
• Shares acquired: 4,255; total value ≈ $11,531.
• Shares owned after transaction: not specified in the filing.
• Footnote: Shares were acquired pursuant to the Issuer's Employee Stock Purchase Plan; the acquisition is exempt under Rule 16b-3(c) and 16b-3(d).
• Filing date: Form 4 filed 2026-07-08 (8 days after the transaction date), which is later than the typical 2-business-day reporting window for insiders.

Context This was an employee purchase under Niagen’s ESPP (not a sale). ESPP purchases by executives are common and reflect participation in company benefit programs; they do not, by themselves, indicate a change in personal investment strategy. The filing notes the exemption under Rule 16b-3 related to compensatory benefit plans.